Maravai Lifesciences Holdings Inc (MRVI) - Total Liabilities
Based on the latest financial reports, Maravai Lifesciences Holdings Inc (MRVI) has total liabilities worth $417.33 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Maravai Lifesciences Holdings Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Maravai Lifesciences Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. See MRVI current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Maravai Lifesciences Holdings Inc Competitors by Total Liabilities
The table below lists competitors of Maravai Lifesciences Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anhui Huaheng Biotechnology Co. Ltd. A
SHG:688639
|
China | CN¥3.36 Billion |
|
Atal SA
WAR:1AT
|
Poland | zł3.25 Billion |
|
Yang Guang Co Ltd
SHE:000608
|
China | CN¥1.77 Billion |
|
Samsung Fire And Marine Ins Pref
KO:000815
|
Korea | ₩71.79 Trillion |
|
Feitian Technologies Co Ltd
SHE:300386
|
China | CN¥135.24 Million |
|
Guangdong Xinhui Meida Nylon Co Ltd
SHE:000782
|
China | CN¥2.17 Billion |
|
ZheJiang RIFA Digital Precision Machinery Co Ltd
SHE:002520
|
China | CN¥1.54 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Maravai Lifesciences Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MRVI market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maravai Lifesciences Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maravai Lifesciences Holdings Inc (2018–2024)
The table below shows the annual total liabilities of Maravai Lifesciences Holdings Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $431.04 Million | -38.21% |
| 2023-12-31 | $697.57 Million | -49.34% |
| 2022-12-31 | $1.38 Billion | +0.30% |
| 2021-12-31 | $1.37 Billion | +23.03% |
| 2020-12-31 | $1.12 Billion | +157.62% |
| 2019-12-31 | $433.17 Million | +10.60% |
| 2018-12-31 | $391.66 Million | -- |
About Maravai Lifesciences Holdings Inc
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Producti… Read more